Latest Product Pipeline News

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

New Murchison Gold Limited delivered a robust December quarter with production exceeding contractual ore sales limits and unveiled high-grade drilling success at the Lydia Gold Prospect, underpinning its growth ambitions.

Structural Monitoring Systems Plc reports a profitable December quarter with 40% revenue growth, driven by strong avionics sales and progress toward FAA certification of its CVM™ technology.

High-Tech Metals has raised $10.7 million through the exercise of nearly 43 million options, bolstering its push towards gold production at the Dam-Damsel project and expanding exploration across its vast Western Australian tenure.

AVITA Medical reported solid 11% revenue growth in 2025 and secured a $60 million credit facility to fuel its next phase of expansion, projecting up to 19% revenue growth in 2026.

AnteoTech secures a significant order from the Serum Institute of India and expands its Life Sciences pipeline with new product developments and global partnerships, positioning for accelerated growth in 2026.

Savannah Goldfields has confirmed significant gold mineralisation at its Red Dam Prospect with new diamond drilling results, highlighting a standout intercept of 2.6m at 34.80 g/t Au. This exploration update reinforces the potential of the Georgetown Gold Project as metallurgical testwork and further drilling are set to follow.

AIC Mines has successfully extended the Jericho copper deposit in Northwest Queensland by approximately 250 metres down-plunge, revealing promising grades of copper, gold, and silver. These results reinforce the deposit’s potential to support future production growth alongside the nearby Eloise mine.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.